Lipid profile in type 2 diabetic patients with new dapagliflozin treatment; actual clinical experience data of six months retrospective lipid profile from single center


Calapkulu M., CANDER S. , ÖZ GÜL Ö. , ERSOY C.

DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, vol.13, no.2, pp.1031-1034, 2019 (Journal Indexed in ESCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 13 Issue: 2
  • Publication Date: 2019
  • Doi Number: 10.1016/j.dsx.2019.01.016
  • Title of Journal : DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS
  • Page Numbers: pp.1031-1034

Abstract

Introduction: Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor that improves glycemic control in patients with type II diabetes mellitus which increasing urinary glucose excretion. With numerous controlled experimental studies of dapagliflozin, evaluation of real-life data after entry into clinical practice is an important condition. In our study, the effects of dapagliflozin (10 mg) on lipid profile were investigated retrospectively.